[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ros1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"ROS1 Gene",23,21,[8,16,22,28,35,42,48,54,61,67,73,79,85,91,97,102,108,114,120,126,132,138,145],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04302025","A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:08.402952Z","2026-06-16T05:54:07.906610Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":14,"content_modified":21},"NCT05118789","A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)",[20],"Phase 1\u002FPhase 2","2026-05-05T02:43:29.649189Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT01639508","Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity",[12],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:29.394895Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06716138","A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors",[32],"Phase 1","2026-08-26T02:15:56.561131Z","2026-05-05T02:43:29.330388Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06333899","Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion",[39],"Early Phase 1","2026-08-26T02:19:00.742020Z","2026-05-05T02:43:29.136961Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04693468","Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial",[32],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:28.961863Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06307795","A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors",[32],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:28.368425Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06745908","Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[58],"Phase 3","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.120702Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07405190","Ivonescimab Alone And With Carboplatin\u002FPemetrexed For NSCLC",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.115654Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05681780","Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",[32],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.992106Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06528691","Entrectinib as a Single Agent in Upfront Therapy for Children \u003C3 Years of Age With NTRK1\u002F2\u002F3 or ROS1-FUSED CNS Tumors",[12],"2026-08-26T02:16:46.951087Z","2026-05-05T02:35:31.919545Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07154706","Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)",[58],"2026-08-26T02:16:38.897933Z","2026-04-29T02:57:57.110427Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[20],"2026-08-26T02:15:39.267524Z","2026-04-29T02:57:57.062678Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT04094610","A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations",[20],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:27.807992Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":40,"content_modified":101},"NCT05004116","A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer",[20],"2026-05-05T02:43:27.261412Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[32],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT03093116","A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",[20],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.489051Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[20],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT03042221","Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy",[],"2026-08-26T02:17:27.435233Z","2026-05-13T02:55:06.106741Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT04900935","Patient-centered, Optimal Integration of Survivorship and Palliative Care",[],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:28.871702Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT04151940","PET\u002FCT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer",[],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.577751Z",{"nct_id":139,"title":140,"phases":141,"status":142,"updated_at":143,"content_modified":144},"NCT06943664","Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer",[12],"NOT_YET_RECRUITING","2026-08-26T02:18:51.833592Z","2026-04-29T02:57:57.162640Z",{"nct_id":146,"title":147,"phases":148,"status":149,"updated_at":150,"content_modified":151},"NCT06074588","Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",[58],"ACTIVE_NOT_RECRUITING","2026-08-03T02:08:28.425355Z","2026-05-05T02:35:31.905794Z"]